HCPCS Level II
M1415
Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
- Category
- M. Medical services
- NDC crosswalk
- None in the loaded CMS ASP file
Codes near M1415
These sit next to M1415 in the CMS Level II file. All M codes
- M1410Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1411Currently on first-line immune checkpoint inhibitors without chemotherapy
- M1412Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
- M1413Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
- M1414Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is in an urgent or emergent situation where delay of treatment would jeopardize the patient's health status; other medical reasons/contraindication)
- M1416Patient received hospice services any time during the performance period
- M1417Patients who are up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination
- M1418Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination because of a medical contraindication documented by clinician
- M1419Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination
- M1420Complete ophthalmologic care mips value pathway